Nektar Therapeutics (NKTR) Other financing activities (2012 - 2026)

Nektar Therapeutics' Other financing activities history runs 15 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Other financing activities rose 57828.57% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $4.0 million (up 127.0% YoY), while the FY2024 annual figure was $15.0 million, changed N/A from the prior year.
• Other financing activities for Q1 2026 stood at $4.1 million, up from -$456000.0 in the prior quarter.
• The five-year high for Other financing activities was $30.0 million in Q1 2024, with the low at -$30.0 million in Q2 2024.
• The 5-year median for Other financing activities is $18000.0 (2023), against an average of $1.3 million.
• Peak annual rise in Other financing activities reached 83238.89% in 2024, while the deepest fall reached 166644.44% in 2024.
• Nektar Therapeutics' Other financing activities stood at $8000.0 in 2022, then plunged by 325.0% to -$18000.0 in 2023, then surged by 83238.89% to $15.0 million in 2024, then sank by 103.05% to -$456000.0 in 2025, then surged by 989.25% to $4.1 million in 2026.
• Business Quant data shows NKTR's Other financing activities at $4.1 million in Q1 2026, -$456000.0 in Q4 2025, and $456000.0 in Q3 2025.